pharmaphorum

JUNE 8, 2021

The entire APAC region already accounts for 30% of all global pharma spending, and within these markets national healthcare expenditure is expected to increase threefold to over $2 trillion by 2030. million in 2030. New cancer cases in China increased from 4 million in 2015 to 4.4 million in 2019, and are estimated to increase to 5.7

Chemotherapy 105

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunity 105

pharmaphorum

JULY 28, 2021

Under the agreement, Calico is responsible for research and early development until 2025 and will take projects through phase 2a trials until 2030, with AbbVie having an option to take over projects once they reach later-stage development and lead commercialisation efforts.

Immunization 59

Immunization Immunity Drug Development 59

pharmaphorum

MARCH 10, 2022

Biologics product development has increased steadily over the past decade, with the volume of business forecast to double by 2030. Driven by advancements in technology, these complex therapeutics have already made waves in life sciences, providing revolutionary treatment options in oncology, immune conditions and rare diseases.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Packaging Immunity 98

Express Pharma

MAY 22, 2023

As the world grappled with the COVID-19 pandemic, and now continues to deal with its aftermath, ‘immunity’ has become the new buzzword and the demand for nutraceuticals across the globe has increased manifold. Read: [link] www.expresspharma.in/six-reasons-why-india-is-poised-to-be-aglobal-leader-in-nutraceuticals/

Dosage 105

Dosage Method Validation Labelling Immunity 105

PharmaShots

MARCH 13, 2023

IgA immune complexes are higher in circulation when patients have respiratory infections such as a cough or sore throat, therefore, many of them end up depositing in the kidneys and this is when patients with IgA nephropathy typically present with symptoms such as hematuria (blood in the urine).

Mayo Clinic 40

Mayo Clinic Immunization Immunity 40

PharmaShots

JUNE 29, 2023

A portmanteau of nutrients and pharmaceuticals, nutraceuticals are colloquially known as medical foods With a market size of $413B in 2021, the nutraceutical market value is forecasted to cross the threshold of $650B by 2030 by marking a remarkable CAGR of 3.9 percent from 2021 to 2030.

Immunization 40

Immunization Immunity 40

European Pharmaceutical Review

MARCH 7, 2024

Firstly, alpha particles exhibit greater biological effectiveness by inducing irreparable DNA double-strand breaks, minimising the risk of resistance or immune escape in tumour cells. However, by employing alpha particles, TAT offers two crucial advantages.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunity Immunization 52

Pharmaceutical Technology

MAY 25, 2023

The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. The World Health Organization (WHO) has set a goal of ending the meningitis epidemic by 2030.

Vaccines 78

Vaccines Immunity Immunization 78

PharmaShots

APRIL 11, 2023

by 2030 at a CAGR of 6.9% Market Size:4 The global hemophilia market size accounted for $12.2B in 2021 and is projected to increase at $22.2B

Immunization 64

Immunization Immunity Vaccines 64

Pharmacy Friday Pearls

MARCH 9, 2022

Crotalidae Polyvalent Immune FAB (Ovine). Crotalidae Immune F(ab’)2 (Equine). 2001;161(16):2030-6. Patients can develop delayed or recurrent hematologic symptoms up to a week after treatment cessation, especially following a severe envenomation. Pharmacology. Cocchio C, et al Am J Health Syst Pharm. 2020;77(3):175-187.

Immunity 40

Immunity Immunization Packaging Labelling 40

pharmaphorum

JUNE 1, 2022

According to the World Health Organization, the world will need more than 40 million new doctors, nurses, frontline healthcare workers, and various other healthcare professionals by 2030. This equates to approximately doubling the current medical workforce.

Vaccines 145

Vaccines Immunization Immunity Hospitals 145

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.

Immunity 116

Immunity Immunization Vaccines 116

European Pharmaceutical Review

SEPTEMBER 1, 2023

billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. During the American Society of Clinical Oncology (ASCO) 2023 annual meeting, BioNTech revealed promising Phase I results for the pancreatic cancer drug BNT122 combined with the immune checkpoint inhibitor (ICI) atezolizumab.

Immunity 110

Immunity Immunization Vaccines 110

pharmaphorum

JANUARY 6, 2023

The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim. It will also cover some infectious disease targets.

Vaccines 111

Vaccines Immunization Immunity Drug Development 111

Pharmaceutical Technology

FEBRUARY 24, 2023

The WHO’s 2020 global strategy sets out its vision of cervical cancer being eliminated as a public health problem by 2030 and outlines a pathway with strategic actions to achieve its goal.

Vaccines 116

Vaccines Communication Medical Schools Immunity 116

Pharmacy Times

NOVEMBER 4, 2022

WHO has released a global plan for hepatitis B elimination by 2030, including goals to increase pediatric and maternal immunization and to improve screening and treatment.

Vaccines 26

Vaccines Immunity Immunization 26

Express Pharma

JANUARY 15, 2025

per cent expected from 2025 to 2030, the event will serve as a hub for Distributors, Procurement Managers, Product Development Experts, Regulatory Affairs Professionals, and R&D specialists. per cent and a forecasted value of USD 12 billion by 2030. In India, a nation of 1.4

Labelling 105

Labelling Immunization Immunity Compounding 105

Pharmaceutical Business Review

DECEMBER 26, 2024

This also stands as a commitment from our side to support the 2030 vision ofSaudi Arabiathrough localising biopharmaceutical products in the Kingdom.” This mechanism is crucial in controlling inflammatory and immune responses.

Biosimilars 52

Biosimilars Immunity Immunization Pharmaceutical Companies 52

European Pharmaceutical Review

JUNE 27, 2022

The Kigali Summit on Malaria and NTDs , hosted by His Excellency (HE) Paul Kagame, President of the Republic of Rwanda, on Thursday 23 June 2022, gathered world leaders to commit to ending these devastating diseases by the end of 2030. Did you know, 1.7

Vaccines 110

Vaccines Communication Documentation Compounding 110

pharmaphorum

SEPTEMBER 16, 2022

Despite the RSV vaccine threat, analysts at GlobalData have predicted that nirsevimab could reach $3 billion in annual revenue by 2030, assuming a launch next year. Both vaccines are also being tested in older adults. In part, that is because of the scale of the public health crisis caused by RSV. Photo by Christian Bowen on Unsplash.

Vaccines 59

Vaccines Immunization Immunity 59